Search Results - "IKEMATSU, HIDEYUKI"

Refine Results
  1. 1

    Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts by Ikematsu, Hideyuki, Hayden, Frederick G, Kawaguchi, Keiko, Kinoshita, Masahiro, de Jong, Menno D, Lee, Nelson, Takashima, Satoru, Noshi, Takeshi, Tsuchiya, Kenji, Uehara, Takeki

    Published in The New England journal of medicine (23-07-2020)
    “…In a randomized, double-blind trial that treated household contacts of patients with influenza with a single dose of baloxavir or placebo, participants taking…”
    Get full text
    Journal Article
  2. 2

    Effect of seasonal vaccination on the selection of influenza A/H3N2 epidemic variants by Chong, Yong, Ikematsu, Hideyuki

    Published in Vaccine (05-01-2017)
    “…Highlights • The effect of vaccination on the dynamics of influenza viruses remains unknown in humans. • Our study showed higher mutations within epitopes in…”
    Get full text
    Journal Article
  3. 3

    Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza by Ikematsu, Hideyuki, Kawai, Naoki

    Published in Expert review of anti-infective therapy (01-10-2011)
    “…Oseltamivir and zanamivir are well-established and well-researched drugs for the treatment of influenza in Japan and the rest of the world. A new neuraminidase…”
    Get more information
    Journal Article
  4. 4

    High genetic stability in MDCK-SIAT1 passaged human influenza viruses by Matsumoto, Shinya, Chong, Yong, Kang, Dongchon, Ikematsu, Hideyuki

    “…MDCK-induced amino acid (AA) mutation, such as D151G/N in the neuraminidase (NA) of influenza A/H3N2 viruses, is of concern. MDCK-SIAT1 cells, modified…”
    Get full text
    Journal Article
  5. 5

    Is seasonal vaccination a contributing factor to the selection of influenza epidemic variants? by Chong, Yong, Ikematsu, Hideyuki

    Published in Human vaccines & immunotherapeutics (04-03-2018)
    “…Influenza A/H3N2 viruses are the most common and virulent subtypes for humans. Antigenic drift, changes in antigenicity through the accumulation of mutations…”
    Get full text
    Journal Article
  6. 6

    Consecutive influenza surveillance of neuraminidase mutations and neuraminidase inhibitor resistance in Japan by Chong, Yong, Matsumoto, Shinya, Kang, Dongchon, Ikematsu, Hideyuki

    Published in Influenza and other respiratory viruses (01-03-2019)
    “…Background The large consumption of neuraminidase inhibitors (NAIs) for the treatment of influenza virus infections places Japan at risk of becoming the…”
    Get full text
    Journal Article
  7. 7

    Spread of predominant neuraminidase and hemagglutinin co-mutations in the influenza A/H3N2 virus genome by Chong, Yong, Ikematsu, Hideyuki

    “…Genetic variation of influenza neuraminidase (NA), unlike for hemagglutinin (HA), has not been fully characterized. Therefore, we determined the relation…”
    Get full text
    Journal Article
  8. 8

    Post-vaccination antibody evaluation for nosocomial SARS-CoV-2 delta variant breakthrough infection by Goto, Takeyuki, Tani, Naoki, Ikematsu, Hideyuki, Gondo, Kei, Oishi, Ryo, Minami, Junya, Onozawa, Kyoko, Kuwano, Hiroyuki, Akashi, Koichi, Shimono, Nobuyuki, Chong, Yong

    Published in PloS one (25-07-2022)
    “…Waning humoral immunity after mRNA vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a significant problem for public health…”
    Get full text
    Journal Article
  9. 9

    Correlation of patient symptoms with SARS-CoV-2 Omicron variant viral loads in nasopharyngeal and saliva samples and their influence on the performance of rapid antigen testing by Shiraishi, Kenichiro, Chong, Yong, Goto, Takeyuki, Ishimaru, Toshiyuki, Shimono, Nobuyuki, Ikematsu, Hideyuki, Akashi, Koichi

    Published in Microbiology spectrum (09-10-2024)
    “…Evaluating SARS-CoV-2 viral loads in nasopharyngeal (NP) and saliva samples, factors affecting viral loads, and the performance of rapid antigen testing (RAT)…”
    Get full text
    Journal Article
  10. 10

    Post-vaccination antibody evaluation for nosocomial SARS-CoV-2 delta variant breakthrough infection by Takeyuki Goto, Naoki Tani, Hideyuki Ikematsu, Kei Gondo, Ryo Oishi, Junya Minami, Kyoko Onozawa, Hiroyuki Kuwano, Koichi Akashi, Nobuyuki Shimono, Yong Chong

    Published in PloS one (13-07-2022)
    “…Waning humoral immunity after mRNA vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a significant problem for public health…”
    Get full text
    Journal Article
  11. 11
  12. 12

    Genetic testing and serological screening for SARS-CoV-2 infection in a COVID-19 outbreak in a nursing facility in Japan by Chong, Yong, Tani, Naoki, Ikematsu, Hideyuki, Terazawa, Nobuto, Nakashima, Hitoshi, Shimono, Nobuyuki, Akashi, Koichi, Tanaka, Yosuke

    Published in BMC infectious diseases (15-03-2021)
    “…The Pandemic of coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has critically impacted the spread of…”
    Get full text
    Journal Article
  13. 13
  14. 14
  15. 15
  16. 16

    In vitro neuraminidase inhibitory activities of four neuraminidase inhibitors against influenza viruses isolated in the 2010–2011 season in Japan by Ikematsu, Hideyuki, Kawai, Naoki, Kashiwagi, Seizaburo

    “…Abstract The half maximal inhibitory concentration (IC50 ) of four neuraminidase inhibitors (NAIs), oseltamivir, zanamivir, laninamivir, and peramivir; was…”
    Get full text
    Journal Article
  17. 17
  18. 18

    Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate; comparison of the 2011/12 to 2015/16 Japanese influenza seasons by Ikematsu, Hideyuki, Kawai, Naoki, Iwaki, Norio, Kashiwagi, Seizaburo

    “…The duration of fever and symptoms after laninamivir octanoate hydrate (laninamivir) inhalation were investigated in the Japanese 2015/16 influenza season, and…”
    Get full text
    Journal Article
  19. 19
  20. 20